[1]Shimada H, Ambros IM, Dehner LP. Terminology and morphologic criteria of neuroblastic tumors recommendations by the international neuroblastoma pathology committee[J]. Cancer, 1999, 86(2): 349-363.
[2]Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993, 11(8): 1466-1477.
[3]Seigel MJ, Ishwaran H, Fletcher BD. Staging of neuroblastoma at imaging of the radiology oncology group[J]. Radiology, 2002, 223(1): 168-175.
[4]Brisse HJ, McCarvilla MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international neuroblatoma risk group project[J]. Radiology, 2011, 261(1): 243-257.
[5]Nour-Eldin NEA, Abdelmonem O, Tawfik AM, et al. Pediatric primary and metastatic neuroblastoma: MRI findings pictorial review[J]. Magn Res Imaging, 2012, 30(7): 893-906.
[6]Zeltzer PM, Marangos PJ, Evans AE, et al. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course[J]. Cancer, 1986, 57(6): 1230-1234.
[7]Massaron S, Seregni E, Luksch R, et al. Neuron-Specific Enolase Evaluation in Patients with Neuroblastoma[J]. Tumor Biol, 1998, 19(4): 261-268.
[8]Tanabe M, Ohnuma N, Iwai J, et al. Bone Marrow Metastases of Neuroblastoma Analyzed by MRI and Its Influence on Prognosis[J]. Med Pediatr Oncol, 1995, 24(5): 292-299.
[9]Shah LM, Hanrahan CJ. MRI of Spinal Bone Marrow: Part 1 Techniques and Normal Age-Related Appearances[J]. AJR, 2011, 197(6): 1298-1308.
[10]Hanrahan CJ, Shah LM. MRI of Spinal Bone Marrow: Part 2, T1-Weighted Imaging-Based Differential Diagnosis[J]. AJR, 2011, 197(6): 1309-1321.
[11]D’Ambrosio N, Lyo JK, Young RJ, et al. Imaging of Metastatic CNS Neuroblastoma[J]. AJR, 2010, 194(5): 1223-1229.
[12]潘恩源，陈丽英. 儿科影像诊断学[M]. 北京：人民卫生出版社，2007：736-741.
[13]张锦华. 小儿神经母细胞瘤[M]. 北京：人民卫生出版社，2009：61-80.
[14]刘菁华，朱珍，张翼. 儿童腹膜后神经母细胞瘤CT特征分析[J]. 国际医学放射学杂志，2014，37（2）：106-109.
[15]李欣，张丽群. 儿童神经母细胞瘤的CT诊断[J]. 中华放射学杂志，1997，31（12）：814-817.
[16]Schleiermacher G, Rubie H, Hartmann O, et al. Treatmentof stage 4s neuroblastoma-report of 10 years’ experience of the French Society of Pediatric oncology[J]. Brit J Cancer, 2003, 89(3): 470-476.
[17]Nickerson HJ, Mathay KK, Seeger RC, et al. Favorable biology and outcome of stage Ⅳ-4 neuroblastoma with supportive care or minimal therapy: A children’s group study[J]. J Clin Oncol, 2000, 18(3):  477-486.
[18]Pasquier E, Kavallaris M, Nicolas André. Metronomic chemotherapy: new rationale for new directions[J]. Nat Rev Clin Oncol, 2010, 7(8): 455-465.
[19]Bahl A, Bakhshi S. Metronomic Chemotherapy in Progressive Pediatric Malignancies: Old Drugs in New Package[J]. Indian J Pediatr, 2012, 79(12): 1617-1622.
[20]Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy[J]. Nat Rev Cancer, 2004, 4(6): 423-436.